Although the combination of systemic administration of a standard dose of TMZ and anti-PD-1 mAbs has been shown to increase the survival rate in murine GBM, no benefit of immune modulation has been observed, and tumors recur [123–125] (Table 2). This evidence concerns the gene PDCD1 and glioblastoma.